- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05800483
Improving Decision-Making for Low Health Literate Prostate CA Patients
Study Overview
Detailed Description
Background: Elicitation of patients' preferences is an integral part of shared decision making, the recommended approach for prostate cancer decision making. However, existing decision aids for this population do not specifically focus on patients' preferences. Healium is a brief interactive web-based decision aid that aims to elicit patient's treatment preferences and is designed for a low health literate population. This study used a randomized controlled trial to evaluate whether Healium (designed to target preference elicitation) is as efficacious as Healing Choices (a comprehensive education and decision tool) in improving outcomes for decision-making and emotional quality of life.
Method: Patients diagnosed with localized prostate cancer who had not yet made a treatment decision were randomly assigned to the brief Healium intervention or Healing Choices, an extensive decision aid previously developed by our group that serves as a virtual information center on prostate cancer diagnosis and treatment. Assessments were completed at baseline, 6-weeks and 3-months post-baseline, and included decisional outcomes (decisional conflict, satisfaction with decision, preparation for decision-making), and emotional quality of life (anxiety/tension and depression), along with demographics, comorbidities, and health literacy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Manhasset, New York, United States, 11030
- Northwell Health
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- a diagnosis of localized prostate cancer and eligible for all treatment options (ie., surgery, radiation, active surveillance);
- had not yet made a treatment decision or begun treatment; and
- have basic proficiency (grade school level) in reading English.
Exclusion Criteria:
• none
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Healium
Healium is a web-based platform that employs a user-centric design and aims to appeal to a low health literate population.
It features a simple language and layout, a large font size, contrasting text and background colors, bright color palette, and use of short labels and headings to describe content.
|
web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
|
|
No Intervention: Comparison (Healing Choices)
The Healing Choices program represents a virtual health center that patients visit to obtain disease and treatment-related information.
The software was designed to be open to exploration with an intuitive layout, without restrictions in terms of order of access.
Information is stored in virtual rooms, such as a library, a conference room showing videos by survivors who discuss their approach to treatment, and physician offices containing videos of physicians representing different treatment specialties.
All information was extensively vetted by health education experts of the National Cancer Institute's Cancer Information Services (CIS).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Decisional Conflict Scale
Time Frame: 6 weeks post-baseline
|
Decisional Conflict was measured with the Decisional Conflict Scale (DCS), a well-validated scale consisting of 16 items that assess four dimensions: informed, clarity, uncertainty, and support.
The response ranges are on a 5-point Likert scale ranging from strongly agree to strongly disagree.
To come up with a total score, the 16 items are summed, divided by 16 and multiplied by 25.
Scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict).
|
6 weeks post-baseline
|
|
Decisional Conflict Scale
Time Frame: 3 months post-baseline
|
Decisional Conflict was measured with the Decisional Conflict Scale (DCS), a well-validated scale consisting of 16 items that assess four dimensions: informed, clarity, uncertainty, and support.
The response ranges are on a 5-point Likert scale ranging from strongly agree to strongly disagree.
To come up with a total score, the 16 items are summed, divided by 16 and multiplied by 25.
Scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict).
|
3 months post-baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Profile of Mood States- Short form
Time Frame: 6 weeks post-baseline
|
The Profile of Mood States (POMS) is a psychological rating scale used to assess transient, distinct mood states.
It is made of subscales for depression, tension, fatigue, confusion, anger, vigor and esteem-related affect.
It consists of 30 items, each measured on a 5-point scale ranging from "not at all" to "extremely".
A total score is calculated by summing the totals for the negative scales and subtracting the totals for the positive scales.
|
6 weeks post-baseline
|
|
Profile of Mood States-Short form
Time Frame: 3 months post-baseline
|
The Profile of Mood States (POMS) is a psychological rating scale used to assess transient, distinct mood states.
It is made of subscales for depression, tension, fatigue, confusion, anger, vigor and esteem-related affect.
It consists of 30 items, each measured on a 5-point scale ranging from "not at all" to "extremely".
A total score is calculated by summing the totals for the negative scales and subtracting the totals for the positive scales.
|
3 months post-baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-192
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.